Cellgen Biopharma Llp - Due diligence report

A 360° intelligence report on Cellgen Biopharma Llp: trust score, financial health, credit view, compliance, directors, growth and distress …

2017-07-13 Delhi, Delhi Converted And Dissolved
Share
Connect MCP
CB Cellgen Biopharma Llp
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Cellgen Biopharma Llp — 360° Intelligence Report

Generated from MCA filings & public records
56/100
Trust Score
Moderate

Cellgen Biopharma Llp is assessed as Moderate with a Trust Score of 56/100. Cellgen Biopharma Llp is a limited liability partnership incorporated in 2017, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and moderate financial risk profile.

Report generated on 03 Oct 2026 from the latest processed filings. Cellgen Biopharma Llp snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Weak

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
56/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
30/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
60/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
70/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
40/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 4 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 70/100 Moderate
  • No open charges - unencumbered balance sheet.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 30/100 Caution Indicated
  • Company status is "Converted And Dissolved" - not Active.
  • Last balance sheet is for Mar 2022 - filings overdue.
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
RAGHVENDRA SINGH KUSHWAH 01234567 Director 01/04/2018 6 yrs Approved
AKHIL GUPTA 01234567 Director 01/04/2018 6 yrs Approved
ANSHITA GARG 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 40
Growth signals & trust indicators
Revenue acceleration: +38% over 3 year(s).
Net margin improved to 1.42.
Operating for 9 years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Statutory filings appear overdue.
Adverse company status: Converted And Dissolved.
Compliance score is weak (30/100).
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence41/100
Caution indicated
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment57/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view65/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 6 events
31 Mar 2022
Latest balance sheet
Filed with ROC
31 Mar 2021
Last AGM held
Annual general meeting
13 Jul 2017
Incorporated
Registered with Roc Delhi
Director appointed
RAGHVENDRA SINGH KUSHWAH (Designated Partner)
Director appointed
AKHIL GUPTA (Designated Partner)
Director appointed
ANSHITA GARG (Designated Partner)
10

Key Observations

Auto-generated from the data above
Revenue grew 2.1x over the last 3 financial year(s).
Net profit margin moved from 24% to 0.86.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Precise Pharmaceuticals U74899PB1993PTC049546 Ludhiana, Punjab, India
Adelson Life Care Private Limited U24100RJ2019PTC064607 Jaipur, Rajasthan, India
Vernell Pharma Private Limited U74999MH2017PTC296511 Thane, Maharashtra, India
Dominus Healthcare Private Limited U24299KA2018PTC115535 Bengaluru, Karnataka, India
Mapaex Remedies Llp AAO-4890 Wadhwan City, Gujarat, India
Adisun Pharma Private Limited U74999PN2017PTC168229 Satara, Maharashtra, India
Wellspring Pharmaceutical Private Limited U51909KA2016PTC096205 Bijapur, Karnataka, India
Numed Laboratories Private Limited U24230MH1988PTC049678 Mumbai, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Cellgen Biopharma Llp before audits and certifications: compliance score 30/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Cellgen Biopharma Llp: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 70/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 75/100, margin trends, ownership structure and peer set for Cellgen Biopharma Llp - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Caution indicated. Trust score 56/100, distress signals and MSME payment-delay disclosures - know whether Cellgen Biopharma Llp pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Cellgen Biopharma Llp - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Cellgen Biopharma Llp an active company?

Cellgen Biopharma Llp has MCA status “Converted And Dissolved” with a compliance score of 30/100 (Caution Indicated).

Is Cellgen Biopharma Llp financially healthy?

Cellgen Biopharma Llp has a Financial Health Score of 60/100 (Moderate) based on its filed financial statements.

Should I do business with Cellgen Biopharma Llp?

Its overall Trust Score is 56/100 (Moderate). Vendor verdict: Caution indicated. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Cellgen Biopharma Llp?

See the directors and ownership sections above for board and shareholding detail. 3 active director(s) are on record.

Does Cellgen Biopharma Llp have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Cellgen Biopharma Llp up to date with its ROC filings?

Last balance sheet is for Mar 2022 - filings overdue. Overall compliance score: 30/100 (Caution Indicated).

Is it risky to lend to Cellgen Biopharma Llp?

Its Credit Risk Score is 70/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.